|Home | About | Journals | Submit | Contact Us | Français|
Stimulant medications, such as methylphenidate, which are effective treatments for attention deficit hyperactivity disorder (ADHD), enhance brain dopamine signaling. However, the relationship between regional brain dopamine enhancement and treatment response has not been evaluated. Here, we assessed whether the dopamine increases elicited by methylphenidate are associated with long-term clinical response. We used a prospective design to study 20 treatment-naive adults with ADHD who were evaluated before treatment initiation and after 12 months of clinical treatment with a titrated regimen of oral methylphenidate. Methylphenidate-induced dopamine changes were evaluated with positron emission tomography and [11C]raclopride (D2/D3 receptor radioligand sensitive to competition with endogenous dopamine). Clinical responses were assessed using the Conners' Adult ADHD Rating Scale and revealed a significant reduction in symptoms of inattention and hyperactivity with long-term methylphenidate treatment. A challenge dose of 0.5 mg/kg intravenous methylphenidate significantly increased dopamine in striatum (assessed as decreases in D2/D3 receptor availability). In the ventral striatum, these dopamine increases were associated with the reductions in ratings of symptoms of inattention with clinical treatment. Statistical parametric mapping additionally showed dopamine increases in prefrontal and temporal cortices with intravenous methylphenidate that were also associated with decreases in symptoms of inattention. Our findings indicate that dopamine enhancement in ventral striatum (the brain region involved with reward and motivation) was associated with therapeutic response to methylphenidate, further corroborating the relevance of the dopamine reward/motivation circuitry in ADHD. It also provides preliminary evidence that methylphenidate-elicited dopamine increases in prefrontal and temporal cortices may also contribute to the clinical response.
Attention deficit hyperactivity disorder (ADHD), which is characterized by symptoms of hyperactivity/impulsivity and inattention, affects ~10% of children (National Institutes of Health, 2000) and 5% of adults (Fayyad et al., 2007) in the United States. Disrupted dopamine (DA) neurotransmission has been implicated in its pathophysiology (Volkow et al., 2007; Prince, 2008). The stimulants drugs methylphenidate (MP) and amphetamine are the primary medications used to treat ADHD (Ilgenli et al., 2007; Rubia et al., 2009), and both enhance DA signaling in brain (Kuczenski and Segal, 1997), which could account for their therapeutic effects. MP increases DA by blocking dopamine transporters (DATs) and amphetamine by releasing DA from the terminal using the DAT as carrier (Kuczenski and Segal, 1997). However, the relationship between DA increases elicited by stimulant medications and the response to clinical treatment in ADHD individuals is not known. The purpose of this study was to investigate whether the magnitude of the DA increases induced by an acute challenge with intravenous MP predicted the clinical response to long-term treatment with oral MP.
For this purpose, we studied20never-medicated adult ADHD subjects, who we treated prospectively over 12 months with a titrated regimen of oral MP. The DA increases to the acute MP challenge were assessed using positron emission tomography (PET) with [ 11C]raclopride (DA D2/D3 receptor radioligand whose specific binding is sensitive to competition by endogenous DA) (Dewey et al., 1993). DA changes were assessed as the differences in the specific binding of [ 11C]raclopride after placebo and after an intravenous challenge with MP (0.5 mg/kg), which mostly reflect MP-induced DA increases (Volkow et al., 1994). We used intravenous rather than oral MP as a pharmacological challenge, because intravenous MP induces more robust and consistent DA responses that when it is given orally (Wang et al., 1999; Volkow et al., 2004). The DA measures were done twice: before initiation of treatment (treatment-naive) and after the 12 months of treatment (long-term treatment) with a titrated regimen of oral MP (~1 mg/kg per day). Clinical symptoms of ADHD were measured using the Conners' Adult ADHD Rating Scale (CAARS) long version (Conners, 1998), also administered before treatment initiation and after 1 year of treatment. Based on our previous finding showing that reduced synaptic DA markers in ventral striatum (VS) (location of the nucleus accumbens) in ADHD were correlated with inattention (Volkow et al., 2009), we hypothesized that the magnitude of the DA increases in VS to MP challenge would predict clinical response to therapeutic doses of oral MP.
We completed assessments in 20 never-medicated adult ADHD subjects (12 females, 8 males) (Table 1 provides clinical and demographic characteristics). ADHD subjects were recruited from clinical referrals to the ADHD programs at Mount Sinai School of Medicine (MSSM), Duke University, and University of California, Irvine (UCI). At least two clinicians interviewed the patients to ensure that they met the Diagnostic and Statistical Manual IV (DSM-IV) diagnostic criteria for ADHD, as evidenced by the presence of at least six of nine inattention symptoms (with or without six of nine hyperactive/impulsive symptoms) as ascertained with a semi-structured interview using DSM-IV criteria. In addition, evidence was required from each subject's history that some symptoms of ADHD were present in childhood (before age 7 years) even when the diagnosis was not made until adulthood. Subjects were excluded if they had a previous history of >3 months of medication treatment for ADHD and excluded if this short treatment occurred within the 6 months before the study.
Because it is estimated that only 10% of adults in the U.S. population meeting the criteria for ADHD are treated at any given time (Kessler et al., 2006), this exclusion criteria did not pose a selection bias. Participants were also excluded if they had a present or past history of substance abuse or dependence (except nicotine; only two participants were smokers). To ascertain past history of substance abuse, participants were asked about present or past substance abuse and underwent urine drug toxicological tests to ensure absence of drug use both at the time of screening and before the PET scan evaluations. Exclusion criteria also included present or past history of a DSM-IV Axis I or II diagnosis (other than ADHD) or neurological disease, medical conditions that may alter cerebral function (i.e., cardiovascular, endocrinological, oncological, or autoimmune diseases), current use of prescribed or over-the-counter medications, and/or head trauma with loss of consciousness of >30 min. All subjects had Hamilton Anxiety (Hamilton, 1959) and Hamilton Depression (Hamilton, 1960) scores < 19. Urine drug screens were obtained on all subjects the day of the PET scan to check for psychoactive drug use. Written informed consent was obtained after complete description of the study to the subjects. Studies were approved by the Institutional Review Boards at Stony Brook University/Brookhaven National Laboratory, MSSM, UCI, and Duke University School of Medicine.
We measured clinical symptoms using the CAARS long version, which provides self-assessment of ADHD symptoms on a 0 (not at all) to 3 (very much) point scale on eight subscales (A, inattention/memory problems; B, hyperactivity/restlessness; C, impulsivity/emotional liability; D, problems with self-concept; E, DSM-IV inattentive symptoms; F, DSM-IV hyperactive-impulsive symptoms; G, DSM-IV symptom total; and H, ADHD index) (Conners, 1998). Scores on the CAARS A, CAARS B, and CAARS G were used to assess the correlations between symptom changes by clinical treatment with MP and the magnitude of the brain DA increases induced by intravenous MP. We restricted correlations to three subscales to limit the number of analyses (also subscales A and E, and subscales B and F include overlapping symptoms). The subscales for inattention and hyperactivity were chosen because they represent the core symptoms of ADHD, and the symptom total subscale was chosen as a measure of severity. Symptom improvement was quantified as the difference in the scores of the CAARS (CAARS A for inattention, CAARS B for hyperactivity, and CAARS H for symptom total) for the measures taken before treatment initiation (treatment-naive) and those after long-term treatment with oral MP (within the week before the scanning session).
Participants had two sets of PET [11C]raclopride scans (with placebo and with intravenous MP): one before treatment initiation (treatment-naive) and one after 12 months of clinical treatment with oral MP (long-term treatment). Clinical treatment with oral MP was provided during the intervening 12 months between scanning sessions. The mean total daily dose of MP was in the vicinity of 1 mg/kg or its equivalent in long-acting dose form [i.e., osmotic release oral system (OROS) MP]. Participants were titrated to a mean dose of 75 mg. The dose is above the maximum labeled dose of OROS MP, because titration was managed according to clinical best practice to maximize efficacy. Progress of treatment was followed using the clinical global impressions improvement and severity scales (Guy, 2000) at each medication visit. Subjects were titrated in open manner during weekly medication visits until they reached optimal response and the dose was stabilized. The PET scans for the long-term treatment condition were conducted 24–48 h after the last clinical dose of MP to allow for the levels of MP from the final dose to dissipate before the PET study (Modi et al., 2000). To corroborate this, we measured plasma MP levels before intravenous injection of MP to ensure that they were nondetectable.
PET scans were obtained with a Siemens HR+ tomograph [resolution, 4.5 × 4.5 × 4.5 mm full-width half-maximum (FWHM)] in 3D mode. Each subject underwent two sets of paired scans with [ 11C]raclopride (total of four scans); for each set, one scan was done after intravenous placebo (3 cc saline) and one after intravenous MP (0.5 mg/kg). The study used a single blind design (subjects were blind to the drugs received). Dynamic scans were started immediately after injection of 4–8 mCi of [ 11C]raclopride (specific activity, 0.5–1.5 Ci/μM at end of bombardment). Dynamic scans were obtained for a total of 60 min as described previously (Volkow et al., 1994). Arterial blood was obtained throughout the procedure to measure the concentration of unchanged [11C]raclopride in plasma (Alexoff et al., 1995).
Regions of interest (ROIs) were obtained directly from the [ 11C]raclopride images as described previously (Volkow et al., 1994). Briefly, we identified the ROI on summed images (dynamic images taken from 10 to 54 min) that were resliced along the intercommissural plane (anterior commissure–posterior commissure line). The caudate, putamen, VS, and cerebellum were measured on four, three, two, and two planes, respectively, and right and left regions were delineated. These regions were then projected to the dynamic scans to obtain concentrations of carbon-11 versus time, which were used to calculate the K1 (transport constant from plasma to tissue) and the distribution volumes (milliliters per grams) and the blood to tissue transport constant (K1) in caudate, putamen, VS, and cerebellum using a graphical analyses technique for reversible systems (Logan plots) (Logan et al., 1990). The measure of binding potential relative to a nondisplaceable reference (BPND) was obtained as the ratio of the distribution volume in striatum to that in cerebellum minus 1 and was used to quantify DA D2/D3 receptor availability. The difference in BPND between MP and placebo (ΔBPND) was used as the measure of DA release. A two-measure within-subject repeated ANOVA to assess for drug effect (placebo vs intravenous MP) and condition (treatment-naive vs long-term treatment) was done to evaluate the effects of intravenous MP on DA and to determine whether this effect was influenced by long-term clinical treatment with oral MP. Pearson's product moment correlation analysis was done to assess whether DA changes were associated with symptom changes while on treatment [difference on the scores for inattention (CAARS A), hyperactivity (CAARS B), and total symptoms (CAARS G) obtained before treatment initiation and those after long-term clinical treatment with oral MP]. To control for potential nonspecific effects of intravenous MP, we also evaluated its effects on K1 and assessed the correlation between changes in K1 (placebo vs intravenous MP) and symptom improvement while on treatment. To control for the contribution of depression and anxiety on MP-induced DA changes, we included the Hamilton scores as covariates in the analyses.
Findings with the ROI analysis were considered significant only if corroborated with Statistical Parametric Mapping (SPM) (Friston et al., 1995). SPM was also used for exploratory analysis to assess the effects of intravenous MP on DA release in extrastriatal brain regions. The SPM analysis was performed on BPND images (obtained by computing the BPND in each pixel). A spatial normalization template matching the average BPND image contrast in the brain was developed using the BPND images from 34 healthy control subjects that participated in previous [ 11C]raclopride studies and collected with the same instrument and scanning sequence used for the present study. All images were carefully inspected to ensure whole-brain coverage and exclude images with potential artifacts. A 12-parameter affine transformation with 16 nonlinear iterations was used to register the images to the PD.mnc Montreal Neurological Institute (MNI) template provided with the SPM2 package. The dimensions of the bounding box of the output volumes were 90:90, 126:90, and 72:108 along x, y, and z, respectively, and the voxel size was 2×2×2 mm3. Bilinear interpolation was used for image reslicing. The average normalized and smoothed image (FWHM, 8 mm) was computed to obtain the BPND template in the MNI stereotactic space. The BPND images of the present study were then spatially normalized to the stereotactic space of MNI using the BPND template and subsequently smoothed with an 8 mm isotropic Gaussian kernel. A within-subject ANOVA model in SPM2 was used to assess for drug effect (placebo vs intravenous MP) and treatment condition (treatment-naive vs long-term treatment) to assess the effects of intravenous MP on DA and to determine whether this effect was affected by long-term clinical MP treatment. Significance was set at p < 0.001 (uncorrected, cluster size threshold > 100 voxels), and the statistical maps were overlaid on an MRI structural image. Pearson's product moment correlations were used to assess the association between MP-induced DA changes (ΔBPND intravenous MP vs placebo) and the changes in the scores on the CAARS A (inattention) and CAARS B (hyperactivity) (Δtreatment-naive vs long-term treatment).
Plasma levels of MP were undetectable before the injection of intravenous MP both in the treatment-naive and long-term treatment conditions. After intravenous MP injection, there were no differences in plasma MP concentrations (nanograms per milliliters) between the treatment-naive and long-term treatment conditions for any of the different time points: 15 min (132 ± 34 vs 134 ± 32, respectively), 30 min (96 ± 17 vs 93 ± 26), 45 min (69 ± 19 vs 74 ± 23), or 60 min (55 ± 14 vs 56 ± 13).
The ROI analysis on the measures of D2/D3 receptor availability (BPND of [ 11C]raclopride) obtained with placebo (without intravenous MP) revealed higher D2/D3 receptor availability for the measures obtained before treatment initiation (treatment-naive) than those obtained after long-term treatment with oral MP, both for caudate (p < 0.005) and putamen (p < 0.006) but not for VS (Table 2). The SPM analysis showed the same trend (p < 0.05 uncorrected), although the effect was not significant when corrected for multiple comparisons with familywise error (pFWE-CORR > 0.05).
Intravenous MP did not change K1 (transport constant of radiotracer from plasma to tissue) in striatum for neither the naive nor long-term treatment condition (Table 2). Conversely, intravenous MP significantly reduced D2/D3 receptor availability in striatal regions (caudate, putamen, VS) (Fig. 1) (Table 2). Comparison between conditions revealed that the reductions in BPND with intravenous MP were significantly higher for the treatment-naive than for the long-term treatment condition in putamen (26 ± 7 vs 18 ± 10%, p < 0.01, respectively) and showed a trend in VS (18±15vs9± 15%, p < 0.07); in caudate, the difference was not statistically significant (10 ± 8 vs 5 ± 10%) (Table 2).
The SPM analysis corroborated a significant decrease (PFWE-CORR < 0.05) in striatal D2/D3 receptor availability with intravenous MP for both the treatment-naive and long-term treatment conditions (Fig. 2, Table 3) and corroborated the significantly larger decreases in D2/D3 receptor availability elicited by the intravenous MP challenge before treatment (treatment-naive) than after long-term treatment in putamen and VS (Fig. 2, Table 3).
In addition, the SPM analysis identified several extrastriatal regions in which the intravenous MP challenge significantly decreased D2/D3 receptor availability, including frontal and temporal cortical regions (Fig. 2, Table 3). The decreases in D2/D3 receptor availability in these cortical regions did not differ between the treatment-naive and long-term treatment conditions.
After the SPM findings, we extracted ROIs in prefrontal cortex and assessed the effects of intravenous MP on K1 and in D2/D3 receptor availability and showed that, although intravenous MP did not affect K1, it significantly decreased D2/D3 receptor availability (Table 2).
None of these findings was affected when we used as covariates the scores on the Hamilton's Depression and Anxiety scales.
The prospective clinical treatment with MP was associated with a significant decrease in average ratings of ADHD symptoms. All scales of the CAARS were significantly higher before treatment initiation than after 1 year of treatment with the titrated regimen or oral MP (Table 1).
The ROI analysis revealed that the correlations between improvement in clinical symptoms with oral MP treatment (before treatment initiation vs after long-term treatment) and the DA increases elicited by intravenous MP (quantified as decreases in D2/D3 receptor availability) were significant for the measures obtained after long-term treatment but not with those obtained before treatment initiation (treatment-naive). Specifically, these correlations were significant for MP-induced DA increases in VS (but not for caudate or putamen) for the ratings of inattention (CAARS A, r = 0.70, p < 0.001) and showed a trend for ratings of hyperactivity (CAARS B, r = 0.50, p < 0.03) and total symptoms (CAARS G, r = 0.54, p < 0.02). Subjects with the larger DA increases in VS with intravenous MP had the greatest reduction in symptoms with long-term MP treatment.
The SPM results for the voxelwise analysis corroborated the significant correlation between DA increases elicited by intravenous MP in VS and the reduction in symptoms of inattention (CAARS A) after long-term treatment and also identified a significant correlation with DA increases in other striatal regions (caudate and putamen) and prefrontal (BA 8, BA 9, BA 24) and temporal (BA 22) cortices (Fig. 3, Table 4). However, the correlations with hyperactivity (CAARS B) or total symptoms (CAARS G) did not reach significance.
The correlations between the differences in K1 (placebo vs intravenous MP) and improvement in clinical symptoms during treatment (changes in scores in CAARS A, CAARS B, CAARS G) were not significant for either striatal or cortical regions (for either naive or long-term treatment conditions).
Here we report several new neurobiological findings about ADHD and MP. First, we show that intravenous MP-induced increases in brain DA were associated with degree of clinical response in a prospective clinical trial of oral MP. Furthermore, we showed that the DA increases in a crucial brain region for reward and motivation (the VS) were associated with improvement in symptoms of inattention. In addition, our SPM analyses showed evidence of MP-induced DA increases in prefrontal and temporal cortices that were also associated with decreases in ratings of inattention. Finally, we document an attenuation of MP-induced DA increases in striatum and a trend toward lower baseline levels of D2/D3 receptor availability in striatum after long-term treatment with oral MP.
Our findings are consistent with previous [ 11C]raclopride studies in healthy controls (Volkow et al., 1997; Martinez et al., 2003) and in adolescents and adults with ADHD (Rosa-Neto et al., 2005; Volkow et al., 2007) showing that MP significantly increases DA in striatum. Historically, the core feature of ADHD has been characterized as one of an attention deficit, but increasing evidence suggests that a reward and motivation deficit may be of equal importance (Haenlein and Caul, 1987; Sonuga-Barke, 2003; Tripp and Wickens, 2008; Castellanos, 2009; Volkow et al., 2009). Indeed, we had proposed that MP, by increasing DA in VS (central brain region for motivation and reward; Wise, 2002) would enhance the saliency of the task, thus improving attention in ADHD (Volkow et al., 2001, 2004), and our current finding of a correlation between MP-induced DA increases in VS and reductions in inattention support this. They are also consistent with previous findings of an association between DA markers in the VS and symptoms of inattention and with reduced scores in a trait measure of motivation in adults with ADHD (Volkow et al., 2011). In ADHD, the decreased DA synthesis of adolescents in nucleus accumbens (located in VS) was also correlated with symptoms of inattention (Forssberg et al., 2006), suggesting that our findings may also pertain to adolescents with ADHD.
The correlations with ratings of hyperactivity were not corroborated by SPM, which may have reflected the low scores in symptoms of hyperactivity in our subjects. Alternatively, it could reflect involvement of noradrenergic effects in reducing hyperactivity (Tilley and Gu, 2008).
Intravenous MP significantly reduced D2/D3 receptor availability in prefrontal and temporal cortices, presumably from DA increases. Although the accuracy of [11C]raclopride to measure DA changes in cortical regions is limited (Egerton et al., 2009), the consistency across both assessments and the high level of statistical significance suggest that these are reliable effects. Moreover, the lack of an effect of intravenous MP on K1 suggests that decreased delivery of the radiotracer to the cortex did not contribute to the decrease in D2/D3 receptor availability. Indeed, others have reported DA increases in prefrontal and temporal cortices with drug challenges (tetrahydrocannabinol and methamphetamine) using [ 11C]raclopride (Piccini et al., 2003; Stokes et al., 2010). Moreover, a previous study showed that oral MP (0.63 mg/kg) increased DA in prefrontal and temporal cortices in controls using [ 11C]FLB 457 [(S)-5-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3-dimethoxybenzamide monohydrobromide] (Montgomery et al., 2007).
Decreases in D2/D3 receptor availability with intravenous MP in prefrontal and temporal cortices were associated with decreased ratings of inattention when subjects were clinically treated, which suggests that enhancement of DA signaling in these cortical regions may contribute to the therapeutic actions of oral MP. MP could ameliorate inattention by both enhancing saliency (through effects on VS) and enhancing the executive components of attention that are mediated through prefrontal regions (including cingulate gyrus) (Fan et al., 2005). Although prefrontal regions expresses low DAT levels (Sesack et al., 1998), MP also blocks norepinephrine transporters (Hannestad et al., 2010), which in prefrontal cortex contribute to DA reuptake and mediate DA increases (Carboni et al., 1990; Morón et al., 2002).
A key component of the DA-deficit theory of ADHD proposes that MP treatment enhances DA in the prefrontal cortex and this contributes to its therapeutic effects (Arnsten, 2009), and fMRI studies support this (Bush et al., 2008). Although much less investigated, there is also evidence of the involvement of temporal cortical regions in ADHD (Kobel et al., 2010) and on their sensitivity to MP (Rubia et al., 2009).
Long-term treatment with MP decreased MP-induced DA increases in striatum but not in cortex. MP increases DA by blocking DAT (Volkow et al., 2001; Spencer et al., 2006), which is the main mechanism for removal of DA from the extracellular space (Gainetdinov and Caron, 2003), and thus the magnitude of the DA increase is derived both by the level of DAT blockade and the amount of DA released (Volkow et al., 2002). Because MP blood levels are associated with the level of DAT blockade (Volkow et al., 1998) and the concentration of MP in plasma after intravenous MP did not differ for treatment-naive and long-term treatment conditions, the lower DA increases in striatum over the year of treatment suggest changes that decrease DA release. These reductions are likely to reflect neuroplasticity effects of chronic MP treatment rather than natural decline because, in healthy controls, DA increases induced by amphetamine were higher (not lower) when subjects were retested 12 months later without any therapeutic intervention (Boileau et al., 2006). This interpretation is consistent with some clinical findings that suggest tolerance to the beneficial effects of MP with long-term treatment, in follow-up studies of ADHD cohorts (Swanson et al., 2008; Molina et al., 2009).
The mechanism(s) that may result in reduced striatal DA release with chronic MP are unclear. They could reflect increased sensitivity of DA autoreceptors that inhibit DA release (Aghaja-nian and Bunney, 1977) or upregulation of DATs that remove extracellular DA (Gainetdinov and Caron, 2003). Decreases could also reflect adaptations in cortical regions that regulate DA release (i.e., frontostriatal pathways) (Karreman and Moghad-dam, 1996). Because the attenuation was in striatum and not in cortical regions, this suggests that they reflect changes in DA autoreceptor sensitivity and/or DAT upregulation because cortical DA projections are much less sensitive to regulation by DA autoreceptors or DAT (Lammel et al., 2008). Indeed, we recently showed that 12 month treatment with oral MP resulted in upregulation of DAT in striatum (Wang et al., 2009).
The ROI analysis revealed that baseline measures of D2/D3 receptor availability in dorsal striatum (placebo measures) were lower after long-term treatment with oral MP than before treatment (treatment-naive), but SPM did not corroborate this unless we decreased significance to puncorr < 0.05. Thus, larger samples are needed to confirm this. Baseline measures of D2/D3 receptor availability in putamen (naive condition) were higher than those we reported in another group of naive ADHD adults (3.64 vs 3.44) but similar to the controls from that study (3.63) (Volkow et al., 2007). These differences are likely to reflect intersubject variability as well as noncontrolled variables that influence D2/D3 receptor availability (i.e., sleep deprivation) (Volkow et al., 2008).
Changes in [ 11C]raclopride binding are related to extracellular DA, but the relationship with synaptic DA is not completely understood (Gjedde et al., 2005). The [ 11C]raclopride method is best suited for regions with high D2/D3 receptor density, such as striatum, and much less sensitive to cortical regions, which renders our cortical findings as preliminary. ROIs were obtained directly from the [ 11C]raclopride images and not from MRIs but, because measures of D2/D3 receptor availability obtained using ROIs selected directly from [ 11C]raclopride images do not differ from those selected from the subject's MRIs (Wang et al., 1996), this is unlikely to have influenced our findings. We show dampening of the DA-enhancing effects of MP after long-term treatment, but we cannot determine whether this is associated with tolerance to clinical efficacy, whether it is long lasting or dissipates promptly. Because of ethical reasons, we did not use a group of untreated ADHD controls to rule out the possibility that the attenuation reflects an age-related decline. To assess clinical efficacy, we did not use a measure of cognitive performance because we were interested in assessing the relationship between enhancement of DA signaling by MP and symptom improvement, which is why we selected the CAARS, an instrument with extensive validity for its use to monitor treatment response in ADHD (Rösler et al., 2010). In our study, we did not obtain measures of motivation, which would have allowed us to test whether DA increases in VS were associated with increased motivation while on clinical treatment. Finally, this study focused on DA, and future studies are necessary to evaluate the noradrenergic effects of MP.
In summary, we show an association between the DA increases elicited by a challenge with intravenous MP in the VS and the improvement in ratings of inattention with long-term oral MP treatment, which provides evidence that the enhancement of DA signaling by MP in VS (a key brain region involved with reward and motivation) is involved in its therapeutic benefits in ADHD. We also give preliminary evidence that MP increases DA in prefrontal and temporal cortices, which may betherapeutically relevant, and that chronic treatment with oral MP may result in adaptations in striatal DA signaling.
This research was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Alcoholism and Alcohol Abuse), National Institute of Mental Health Grant R01MH66961 (G.-J.W.), with infrastructure support from U.S. Department of Energy/Office of Biological and Environmental Research Grant DE-ACO2-76CH00016. We thank the following: David Schlyer and Michael Schueller for cyclotron operations; Donald Warner, David Alexoff, and Paul Vaska for PET operations; Richard Ferrieri, Colleen Shea, Youwen Xu, Lisa Muench, and Payton King for radiotracer preparation and analysis, Karen Apelskog-Torres for study protocol preparation; Millard Jayne, Joseph English, Allan Chrisman, Barbara Hubbard, and Pauline Carter for patient care; and Ruben Baler and Denise Pintello for editorial assistance. This paper was presented at the Society of Nuclear Medicine in 2011.
Author contributions: N.D.V., G.-J.W., D.T., S.H.K., T.L.W., J.H.N., F.W.T., J.S.F., J.L., and J.S. designed research; N.D.V., G.-J.W., D.T., S.H.K., T.L.W., J.H.N., F.W.T., J.S.F., and J.L. performed research; C.T.W. contributed unpublished reagents/analytic tools; N.D.V. and C.T.W. analyzed data; N.D.V. wrote the paper.